GIPR Agonism Inhibits PYY-Induced Nausea-Like Behavior
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
The induction of nausea and emesis is a major barrier to maximizing the weight loss profile of obesity medications, and therefore, identifying mechanisms that improve tolerability could result in added therapeutic benefit. The development of peptide YY (PYY)-based approaches to treat obesity are no exception, as PYY receptor agonism is often accompanied by nausea and vomiting. Here, we sought to determine whether glucose-dependent insulinotropic polypeptide (GIP) receptor (GIPR) agonism reduces PYY-induced nausea-like behavior in mice. We found that central and peripheral administration of a GIPR agonist reduced conditioned taste avoidance (CTA) without affecting hypophagia mediated by a PYY analog. The receptors for GIP and PYY (Gipr and Npy2r) were found to be expressed by the same neurons in the area postrema (AP), a brainstem nucleus involved in detecting aversive stimuli. Peripheral administration of a GIPR agonist induced neuronal activation (cFos) in the AP. Further, whole-brain cFos analyses indicated that PYY-induced CTA was associated with augmented neuronal activity in the parabrachial nucleus (PBN), a brainstem nucleus that relays aversive/emetic signals to brain regions that control feeding behavior. Importantly, GIPR agonism reduced PYY-mediated neuronal activity in the PBN, providing a potential mechanistic explanation for how GIPR agonist treatment reduces PYY-induced nausea-like behavior. Together, the results of our study indicate a novel mechanism by which GIP-based therapeutics may have benefit in improving the tolerability of weight loss agents.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gut hormone PYY3-36 physiologically inhibits food intake
Batterham, R. L., Cowley, M. A., Small, C. J., Herzog, H., Cohen, M. A., Dakin, C. L., Wren, A. M., Brynes, A. E., Low, M. J., Ghatei, M. A., et al. (2002) · Nature · doi:10.1038/nature00887 · Cited by 2,351
Pharmacology, physiology, and mechanisms of incretin hormone action.
Campbell, J. E., & Drucker, D. J. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.04.008 · Cited by 1,500
Coskun, T., Sloop, K. W., Loghin, C., Alsina-Fernandez, J., Urva, S., Bokvist, K. B., Cui, X., Briere, D. A., Cabrera, O., Roell, W. C., et al. (2018) · Molecular Metabolism · doi:10.1016/j.molmet.2018.09.009 · Cited by 882 · cited 1×
“Wild-type (WT) and Gipr-deficient (Gipr / ) mice on a C57BL/6 genetic background (29,30) were maintained at Taconic Contract Breeding.”
Self-citationUnimolecular Dual Incretins Maximize Metabolic Benefits in Rodents, Monkeys, and Humans
Finan, B., Ma, T., Ottaway, N., Müller, T. D., Habegger, K. M., Heppner, K. M., Kirchner, H., Holland, J., Hembree, J., Raver, C., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3007218 · Cited by 696 · cited 1×
“Further, chronic treatment of obese mice with GIPR agonists enhances the anorectic action of glucagon-like peptide 1 receptor (GLP-1R) agonism and delivers synergistic weight loss (17).”
BackgroundHow May GIP Enhance the Therapeutic Efficacy of GLP-1?
Samms, R. J., Coghlan, M. P., & Sloop, K. W. (2020) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2020.02.006 · Cited by 419
Self-citationBettge, K., Kahle, M., Abd El Aziz, M. S., Meier, J. J., & Nauck, M. A. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12824 · Cited by 374
Gut Hormones and Appetite Control: A Focus on PYY and GLP-1 as Therapeutic Targets in Obesity
Silva, A. D., & Bloom, S. R. (2012) · Gut and Liver · doi:10.5009/gnl.2012.6.1.10 · Cited by 373 · cited 1×
“However, efforts to develop PYY-based approaches to treat obesity have been hampered by the occurrence of nausea and vomiting on treatment with PYY-derived analogs (26,27).”
BackgroundAdriaenssens, A. E., Biggs, E. K., Darwish, T., Tadross, J., Sukthankar, T., Girish, M., Polex-Wolf, J., Lam, B. Y., Zvetkova, I., Pan, W., et al. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.07.013 · Cited by 324 · cited 3×
“Additionally, chemogenetic activation of GIPR(1) cells in the ARC reduces feeding in mice (12),”
BackgroundZhang, Q., Delessa, C. T., Augustin, R., Bakhti, M., Colldén, G., Drucker, D. J., Feuchtinger, A., Caceres, C. G., Grandl, G., Harger, A., et al. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2021.01.015 · Cited by 322 · cited 4×
“Peripherally administered GIP stimulates neuronal activity and augments the anorectic efficacy of GLP-1R agonism (15).”
BackgroundInfluentialArea postrema cell types that mediate nausea-associated behaviors
Zhang, C., Kaye, J. A., Cai, Z., Wang, Y., Prescott, S. L., & Liberles, S. D. (2021) · Neuron · doi:10.1016/j.neuron.2020.11.010 · Cited by 263
GDF15 induces anorexia through nausea and emesis
Borner, T., Shaulson, E. D., Ghidewon, M. Y., Barnett, A. B., Horn, C. C., Doyle, R. P., Grill, H. J., Hayes, M. R., & De Jonghe, B. C. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2019.12.004 · Cited by 255 · cited 2×
“GDF15induced gastrointestinal malaise is mediated through binding to its receptor (GFRAL) on neurons located in the AP and NTS (31,33).”
BackgroundSelf-citationOptimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism
Mroz, P. A., Finan, B., Gelfanov, V., Yang, B., Tschöp, M. H., DiMarchi, R. D., & Perez-Tilve, D. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2018.12.001 · Cited by 229
Borner, T., Geisler, C. E., Fortin, S. M., Cosgrove, R., Alsina-Fernandez, J., Dogra, M., Doebley, S., Sanchez-Navarro, M. J., Leon, R. M., Gaisinsky, J., et al. (2021) · Diabetes · doi:10.2337/db21-0459 · Cited by 202 · cited 3×
“Intriguingly, in addition to enhancing the anorectic action of GLP-1R agonism, GIPR activation has been shown to block emesis in ferrets, musk shrews, and dogs and attenuate nausea-like behavior in mice and rats (14,18,19).”
BackgroundSelf-citationDrug therapy in obesity: a review of current and emerging treatments
Williams, D. M., Nawaz, A., & Evans, M. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00816-y · Cited by 195 · cited 1×
“Thus, since a major challenge to the therapeutic utility of weight loss medications is dose-limiting nausea/ vomiting (2,3), our findings have therapeutic relevance in indicating that GIPR agonism could be leveraged to offset tolerability issues that occur with many diabetes medications.”
BackgroundParabrachial Calcitonin Gene-Related Peptide Neurons Mediate Conditioned Taste Aversion
Carter, M. E., Han, S., & Palmiter, R. D. (2015) · The Journal of Neuroscience · doi:10.1523/jneurosci.3729-14.2015 · Cited by 180 · cited 1×
“Although GDF15 responsive and CGRP-expressing PBNV neurons are well characterized (9,34), the roles of PYY-responsive PBND neurons we identified here are less well understood.”
BackgroundSamms, R. J., Sloop, K. W., Gribble, F. M., Reimann, F., & Adriaenssens, A. E. (2021) · Diabetes · doi:10.2337/dbi21-0002 · Cited by 49
Self-citation
Research works printed but not linked: 27
- Srivastava, 2018, Current pharmacotherapy for obesity, Nat Rev Endocrinol, 14, 12, 10.1038/nrendo.2017.122 · DOI · Paper page
- Saper, 2016, The house alarm, Cell Metab, 23, 754, 10.1016/j.cmet.2016.04.021 · DOI
- Horn, 2008, Why is the neurobiology of nausea and vomiting so important?, Appetite, 50, 430, 10.1016/j.appet.2007.09.015 · DOI
- Andermann, 2017, Toward a wiring diagram understanding of appetite control, Neuron, 95, 757, 10.1016/j.neuron.2017.06.014 · DOI · Paper page
- Miller, 1994, The area postrema and vomiting, Front Neuroendocrinol, 15, 301, 10.1006/frne.1994.1012 · DOI · Paper page
- Chen, 2018, Parabrachial CGRP neurons establish and sustain aversive taste memories, Neuron, 100, 891, 10.1016/j.neuron.2018.09.032 · DOI · Paper page
- Adriaenssens, 2020, The glucose-dependent insulinotropic polypeptide signaling axis in the central nervous system, Peptides, 125, 170194, 10.1016/j.peptides.2019.170194 · DOI · Paper page
- Costa, 2022, Anorectic and aversive effects of GLP-1 receptor agonism are mediated by brainstem cholecystokinin neurons, and modulated by GIP receptor activation, Mol Metab, 55, 101407, 10.1016/j.molmet.2021.101407 · DOI · Paper page
- Hayes, 2021, The role of GIP in the regulation of GLP-1 satiety and nausea, Diabetes, 70, 1956, 10.2337/dbi21-0004 · DOI · Paper page
- le Roux, 2008, Supraphysiological doses of intravenous PYY3-36 cause nausea, but no additional reduction in food intake, Ann Clin Biochem, 45, 93, 10.1258/acb.2007.007068 · DOI · Paper page
- Halatchev, 2005, Peripheral administration of PYY(3-36) produces conditioned taste aversion in mice, Cell Metab, 1, 159, 10.1016/j.cmet.2005.02.003 · DOI · Paper page
- Rangwala, 2019, A long-acting PYY3-36 analog mediates robust anorectic efficacy with minimal emesis in nonhuman primates, Cell Metab, 29, 837, 10.1016/j.cmet.2019.01.017 · DOI · Paper page
- Briere, 2018, Mechanisms to elevate endogenous GLP-1 beyond injectable GLP-1 analogs and metabolic surgery, Diabetes, 67, 309, 10.2337/db17-0607 · DOI · Paper page
- Worth, 2020, The cytokine GDF15 signals through a population of brainstem cholecystokinin neurons to mediate anorectic signalling, eLife, 9, e55164, 10.7554/eLife.55164 · DOI · Paper page
- Perens, 2021, An optimized mouse brain atlas for automated mapping and quantification of neuronal activity using iDISCO+ and light sheet fluorescence microscopy, Neuroinformatics, 19, 433, 10.1007/s12021-020-09490-8 · DOI
- Palmiter, 2018, The parabrachial nucleus: CGRP neurons function as a general alarm, Trends Neurosci, 41, 280, 10.1016/j.tins.2018.03.007 · DOI · Paper page
- Gimeno, 2020, Leveraging the gut to treat metabolic disease, Cell Metab, 31, 679, 10.1016/j.cmet.2020.02.014 · DOI · Paper page
- Schmidt, 2014, Effects of PYY3-36 and GLP-1 on energy intake, energy expenditure, and appetite in overweight men, Am J Physiol Endocrinol Metab, 306, E1248, 10.1152/ajpendo.00569.2013 · DOI · Paper page
- Neary, 2005, Peptide YY3-36 and glucagon-like peptide-17-36 inhibit food intake additively, Endocrinology, 146, 5120, 10.1210/en.2005-0237 · DOI · Paper page
- De Silva, 2011, The gut hormones PYY 3-36 and GLP-1 7-36 amide reduce food intake and modulate brain activity in appetite centers in humans, Cell Metab, 14, 700, 10.1016/j.cmet.2011.09.010 · DOI · Paper page
- Geisler, 2020, GIP receptor agonism attenuates GLP-1 receptor agonist induced nausea in rodents, Obesity (Silver Spring), 28, 103
- Rodriguez, 2019, Identifying parabrachial neurons selectively regulating satiety for highly palatable food in mice, eNeuro, 6, 10.1523/ENEURO.0252-19.2019 · DOI
- Stein, 2010, Area postrema projects to FoxP2 neurons of the pre-locus coeruleus and parabrachial nuclei: brainstem sites implicated in sodium appetite regulation, Brain Res, 1359, 116, 10.1016/j.brainres.2010.08.085 · DOI · Paper page
- Geerling, 2016, Genetic identity of thermosensory relay neurons in the lateral parabrachial nucleus, Am J Physiol Regul Integr Comp Physiol, 310, R41, 10.1152/ajpregu.00094.2015 · DOI · Paper page
- Kim, 2020, A neural circuit mechanism for mechanosensory feedback control of ingestion, Nature, 580, 376, 10.1038/s41586-020-2167-2 · DOI
- Chiang, 2020, Divergent neural pathways emanating from the lateral parabrachial nucleus mediate distinct components of the pain response, Neuron, 106, 927, 10.1016/j.neuron.2020.03.014 · DOI · Paper page
- Ryan, 2017, Oxytocin-receptor-expressing neurons in the parabrachial nucleus regulate fluid intake, Nat Neurosci, 20, 1722, 10.1038/s41593-017-0014-z · DOI · Paper page
Cited by
Campbell, J. E., Müller, T. D., Finan, B., DiMarchi, R. D., Tschöp, M. H., & D’Alessio, D. A. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2023.07.010 · Cited by 149
The intestine as an endocrine organ and the role of gut hormones in metabolic regulation
Bany Bakar, R., Reimann, F., & Gribble, F. M. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00830-y · Cited by 144
GLP-1 physiology in obesity and development of incretin-based drugs for chronic weight management
Holst, J. J. (2024) · Nature Metabolism · doi:10.1038/s42255-024-01113-9 · Cited by 125
“However, it has been reported that the combination with GIP may limit the side effects of GLP-1 agonism 171 , which means that higher doses may be employed, resulting in greater effects.”
Transforming obesity: The advancement of multi-receptor drugs
Kusminski, C. M., Perez-Tilve, D., Müller, T. D., DiMarchi, R. D., Tschöp, M. H., & Scherer, P. E. (2024) · Cell · doi:10.1016/j.cell.2024.06.003 · Cited by 126
Adriaenssens, A., Broichhagen, J., de Bray, A., Ast, J., Hasib, A., Jones, B., Tomas, A., Burgos, N. F., Woodward, O., Lewis, J., et al. (2023) · JCI Insight · doi:10.1172/jci.insight.164921 · Cited by 77
Self-citation
Metadata
- Authors
- Samms, R. J., Cosgrove, R., Snider, B. M., Furber, E. C., Droz, B. A., Briere, D. A., Dunbar, J., Dogra, M., Alsina-Fernandez, J., Borner, T., De Jonghe, B. C., Hayes, M. R., Coskun, T., Sloop, K. W., Emmerson, P. J., & Ai, M.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2022-05-02
- Volume
- 71
- Issue
- 7
- Pages
- 1410-1423
- ISSN
- 0012-1797 (ISSN-L)
- OpenAlex
- W4225280550
- Cited by
- 69
- References
- 16
- FWCI
- 5.54
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.